AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Eledon Pharmaceuticals, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00241S579
2.30▲ 0.00 (0.00%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
2.30
Day's Range
2.20 – 2.35
52-Week Range
1.35 – 4.60
Volume
418.1K
Avg Volume
780.1K
Share Statistics
Shares Outstanding
Employees
33
Exchange
XNAS
Listed
2014-09-17
Share count as of August 10, 2026

Eledon Pharmaceuticals, Inc. Common Stock (ELDN) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Eledon Pharmaceuticals, Inc. Common Stock (ELDN)
What is Eledon Pharmaceuticals, Inc. Common Stock's Market Cap?
Eledon Pharmaceuticals, Inc. Common Stock's Market Cap is $186.9M, based on as-reported figures from SEC (XBRL) filings.
What is Eledon Pharmaceuticals, Inc. Common Stock's Enterprise Value?
Eledon Pharmaceuticals, Inc. Common Stock's Enterprise Value is $98.1M, based on as-reported figures from SEC (XBRL) filings.
What is Eledon Pharmaceuticals, Inc. Common Stock's Net Income (TTM)?
Eledon Pharmaceuticals, Inc. Common Stock's Net Income (TTM) is -$98.6M, based on as-reported figures from SEC (XBRL) filings.
What is Eledon Pharmaceuticals, Inc. Common Stock's Diluted EPS (TTM)?
Eledon Pharmaceuticals, Inc. Common Stock's Diluted EPS (TTM) is -1.21, based on as-reported figures from SEC (XBRL) filings.
What is Eledon Pharmaceuticals, Inc. Common Stock's Net Debt?
Eledon Pharmaceuticals, Inc. Common Stock's Net Debt is -$88.8M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ELDNAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses
Research and development
General and administrative
Total operating expenses
Loss from operations—
Other income, net
Change in fair value of warrant liabilities
Net loss
Basic earnings per share of common stock—
Diluted earnings per share of common stock—